{"url_path":"/sec/dmaa/10-q/2026/item-2","section_key":"item-2","section_title":"Item 2 Unregistered Sales of Equity Securities and Use of Proceeds.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/2028614/0001213900-26-056798-index.html","accession_number":"0001213900-26-056798","cik":"0002028614","ticker":"DMAA","issuer_name":"Drugs Made In America Acquisition Corp.","edgar_url":"https://www.sec.gov/Archives/edgar/data/2028614/0001213900-26-056798-index.html","primary_entity_key":"0002028614","primary_entity_name":"Drugs Made In America Acquisition Corp."},"word_count":324,"has_tables":true,"body_markdown":"Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.\n\n \n\nOn January 29, 2025, we consummated the Initial\nPublic Offering of 20,000,000 Units at $10.00 per Unit, generating proceeds of $200,000,000. Clear Street LLC acted as sole book-running\nmanager of the Initial Public Offering. The securities in the offering were registered under the Securities Act on registration statement\non Form S-1 (No. 333-281170). The registration statement was declared effective on January 7, 2025 and the post-effective amendment to\nthe registration statement was declared effective on January 27, 2025.\n\n \n\nSimultaneous with the consummation of the Initial\nPublic Offering, we consummated the private placement with the sponsor of 400,000 Private Placement Units at a price of $10.00 per unit,\ngenerating total proceeds of $4,000,000. Each Private Placement Unit consists of one ordinary share and one right to receive one-eighth\n(1/8) of one ordinary share upon the consummation of an initial business combination. The proceeds from the sale of the Private Placement\nUnits were added to the net proceeds from the Initial Public Offering held in the trust account. The issuance was made pursuant to the\nexemption from registration contained in Section 4(a)(2) of the Securities Act.\n\n \n\nOn February 18, 2025, the underwriters exercised\ntheir over-allotment option to purchase an additional 3,000,000 Units at a purchase price of $10.00 per Unit, generating additional gross\nproceeds of $30,000,000. In connection with the underwriters’ exercise of their over-allotment option, the Company also consummated\nthe sale of an additional 30,000 Private Placement Units at $10.00 per Private Unit, generating total proceeds of $300,000. A total of\n$231,150,000 was deposited into the trust account.\n\n \n\nWe paid a total of $8,898,201, consisting of $1,150,000\nof cash underwriting fees, $6,900,000 of deferred underwriting fees, and $848,201 of other offering costs and expenses related to the\nInitial Public Offering.\n\n \n\nFor a description of the use of the proceeds generated\nin our Initial Public Offering, see Part I, Item 2 of this report.\n\n \n\n25"}